Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Chemotherapy/Targeted Therapy-Induced GI Symptoms in GI Cancers
NCT07319364Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of Fecal Microbiota Transplantation Capsule in chemotherapy-induced gastrointestinal toxicity (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence and improvement rate of chemotherapy/targeted therapy-induced gastrointestinal symptoms at 8 weeks. Started Sep 2025; status: recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
chemotherapy-induced gastrointestinal toxicity
Beyond the preview
Go deeper on NCT07319364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07319364.